Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia Aurélie.

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Relation of Heart Rate at Rest and Long-Term (>20 Years) Death Rate in Initially Healthy Middle-Aged Men Xavier Jouven, MD, PhD, Jean Philippe Empana,

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

An assessment by the Statin Liver Safety Task Force: 2014 update

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Jari A. Laukkanen, MD, PhD, Tanjaniina Laukkanen, MSc, Setor K

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

A review of PCSK9 inhibition and its effects beyond LDL receptors

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome Richard M. Turner,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred Rossella Spina,

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol,

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Eveline Oestreicher Stock, MD, Christine T

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

High frequency of type 2 diabetes and impaired glucose tolerance in Japanese subjects with the angiopoietin-like protein 8 R59W variant Jianhui Liu,

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Laura Garvey, MD, Michel S. Makaroun, MD, Visala S

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Magali P. Disdier Moulder, PharmD, PhD, Jenna M

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction François Moreau, PhD, Claire Blanchard,

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Volume 67, Issue 4, Pages (April 2005)

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia Aurélie Delacrétaz, PhD, Frederik Vandenberghe, PhD, Mehdi Gholam-Rezaee, PhD, Nuria Saigi Morgui, PhD, Anaïs Glatard, PharmD, Jacques Thonney, MD, Alessandra Solida-Tozzi, MD, Stéphane Kolly, MD, Sylfa Fassassi Gallo, MD, Philipp Baumann, MD, Sylvie Berney, MD, Sandrine Valloton Zulauff, MD, Jean-Michel Aubry, MD, Roland Hasler, PhD, Karsten Ebbing, MD, Armin von Gunten, MPhil, MD, Philippe Conus, MD, Chin B. Eap, PhD Journal of Clinical Lipidology Volume 12, Issue 1, Pages 219-229 (January 2018) DOI: 10.1016/j.jacl.2017.10.002 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Survival curves for new onset dyslipidemia (NOD) by unadjusted Kaplan-Meier curves. (A) Patient survival curve for NODTC (new onset TC hypercholesterolemia); (B) patient survival curve for NODLDL (new onset LDL-C hypercholesterolemia); (C) patient survival curve for NODTG (new onset hypertriglyceridemia); (D) patient survival curve for NODHDL (new onset HDL-C hypocholesterolemia); and (E) Patient survival curve for NODnon-HDL (new onset non-HDL-C hypercholesterolemia). HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol. Journal of Clinical Lipidology 2018 12, 219-229DOI: (10.1016/j.jacl.2017.10.002) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Survival curves for new onset dyslipidemia (NOD) by unadjusted Kaplan-Meier curves according to early lipid change groups. (A) Patient survival curves for NODTC (new onset TC hypercholesterolemia) according to early 5% TC increase threshold (n = 114). (B) Patient survival curves for NODLDL (new onset LDL-C hypercholesterolemia) according to early 5% LDL-C increase threshold (n = 115). (C) Patient survival curves for NODTG (new onset hypertriglyceridemia) according to early 5% TG increase threshold (n = 84). (D) Patient survival curves for NODHDL (new onset HDL-C hypocholesterolemia) according to early 5% HDL-C decrease threshold (n = 152). (E) Patient survival curves for NODnon-HDL (new onset non-HDL-C hypercholesterolemia) according to early 5% non-HDL-C increase threshold (n = 127). HDL-C, high-density lipoprotein cholesterol; HDLd, HDL-C decrease; LDL-C, low-density lipoprotein cholesterol; LDLi, LDL-C increase; TC, total cholesterol; TCi, TC increase; TGi, TG increase. Journal of Clinical Lipidology 2018 12, 219-229DOI: (10.1016/j.jacl.2017.10.002) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 3 Survival curves for new onset dyslipidemia (NOD) by unadjusted Kaplan-Meier curves according to the number of early exceeded thresholds (EETs). NOD was defined as positive if one (or more) of the 4 lipid traits outreached clinical thresholds and/or if patients received a lipid-lowering comedication during psychotropic treatment (n = 86). Journal of Clinical Lipidology 2018 12, 219-229DOI: (10.1016/j.jacl.2017.10.002) Copyright © 2017 National Lipid Association Terms and Conditions